Trial · NCT02470403
Results by group119
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 119
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Percent Change in Body Weight From Baseline to Week 12 | Part 1: LIK066 150 mg Once Daily (qd) | All subjects (n= 42, 43) | -5.51 | 80% Confidence Interval -6.09 to -4.93 | percent change |
| Part 1: Percent Change in Body Weight From Baseline to Week 12 | Part 1: Placebo Once Daily | All subjects (n= 42, 43) | 0.19 | 80% Confidence Interval -0.39 to 0.78 | percent change |
| Part 1: Percent Change in Body Weight From Baseline to Week 12 | Part 1: LIK066 150 mg Once Daily (qd) | Dysglycemic subjects (n= 22, 23) | -6.55 | 80% Confidence Interval -7.34 to -5.77 | percent change |
| Part 1: Percent Change in Body Weight From Baseline to Week 12 | Part 1: Placebo Once Daily | Dysglycemic subjects (n= 22, 23) | 0.29 | 80% Confidence Interval -0.50 to 1.09 | percent change |
| Part 1: Percent Change in Body Weight From Baseline to Week 12 | Part 1: LIK066 150 mg Once Daily (qd) | Normoglycemic subjects (n= 20,20) | -4.46 | 80% Confidence Interval -5.31 to -3.60 | percent change |
| Part 1: Percent Change in Body Weight From Baseline to Week 12 | Part 1: Placebo Once Daily | Normoglycemic subjects (n= 20,20) | 0.09 | 80% Confidence Interval -0.77 to 0.94 | percent change |
| Part 1: Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Part 1: LIK066 150 mg Once Daily (qd) | With at least one AE (any AE) | 43 | Patients | |
| Part 1: Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Part 1: Placebo Once Daily | With at least one AE (any AE) | 39 | Patients | |
| Part 1: Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Part 1: LIK066 150 mg Once Daily (qd) | Serious AE | 1 | Patients | |
| Part 1: Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Part 1: Placebo Once Daily | Serious AE | 0 | Patients | |
| Part 1: Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Part 1: LIK066 150 mg Once Daily (qd) | Death | 0 | Patients | |
| Part 1: Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Part 1: Placebo Once Daily | Death | 0 | Patients | |
| Part 1 and Part 2: Percent Change in Body Weight From Baseline to Week 2 (Day 14) | Part 1: LIK066 150 mg Once Daily (qd) | -1.17 | 80% Confidence Interval -2.21 to -0.12 | Percent change | |
| Part 1 and Part 2: Percent Change in Body Weight From Baseline to Week 2 (Day 14) | Part 2: LIK066 75 mg Twice Daily (Bid) | -1.73 | 80% Confidence Interval -2.75 to -0.70 | Percent change | |
| Part 1 and Part 2: Percent Change in Body Weight From Baseline to Week 2 (Day 14) | Part 2: LIK066 50 mg Three Times Daily (Tid) | -1.71 | 80% Confidence Interval -2.74 to -0.69 | Percent change | |
| Part 1 and Part 2: Percent Change in Body Weight From Baseline to Week 2 (Day 14) | Part 1 and 2 : Pooled Placebo | 0.66 | 80% Confidence Interval -0.46 to 1.79 | Percent change | |
| Part 2: Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Part 2: LIK066 75 mg Twice Daily (Bid) | At least one AE (Any AE) | 40 | Patients | |
| Part 2: Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Part 2: LIK066 50 mg Three Times Daily (Tid) | At least one AE (Any AE) | 43 | Patients | |
| Part 2: Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Part 2: Placebo Three Times Daily | At least one AE (Any AE) | 10 | Patients | |
| Part 2: Number of Patients With Any Adverse Events, Serious Adverse Events and Death | Part 2: LIK066 75 mg Twice Daily (Bid) | Serious AE | 0 | Patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02470403/results